Recombinant activated Factor VII in major surgery and trauma patients: a response.
The review article by Wilson et al. (Expert Opin. Drug Saf., 2005) on recombinant activated Factor VII (rFVIIa) offers some valuable insights into the ongoing exploration of this agent in the management of uncontrolled bleeding--an area of high unmet clinical need. This editorial highlights that the chosen citation of Riou et al. (Shock, 2004), in reference to two parallel studies conducted in trauma patients with blunt and penetrating injury, was both a report of an early analysis of the data, and was only one of several abstracts on these studies published in 2004. The authors of this editorial believe that the inclusion of the other published abstracts in this series would have provided a more comprehensive and balanced overview of recombinant activated Factor VII.
Zakhary
Randa Grob
RG
Seremetis
Stephanie
S
D019317:Evidence-Based Medicine; D015944:Factor VIIIa / Q000009:adverse effects* / Q000627:therapeutic use*; D006470:Hemorrhage / Q000188:drug therapy*; D006801:Humans; D011994:Recombinant Proteins; D014949:Wounds, Nonpenetrating / Q000150:complications* / Q000601:surgery; D014950:Wounds, Penetrating / Q000150:complications* / Q000601:surgery
D011994:Recombinant Proteins; D015944:Factor VIIIa